Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "NAGI"

1728 News Found

Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%
News | May 18, 2026

Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%

US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya


Surya Hospitals expands advanced women-centric health services
Hospitals | May 18, 2026

Surya Hospitals expands advanced women-centric health services

New facility ‘Amber Wing’ adds 55 beds and strengthens surgical, cardiac, robotic and preventive care infrastructure for women in Mumbai


Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review
News | May 18, 2026

Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review

The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million


Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority
Drug Approval | May 15, 2026

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026


Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore
News | May 15, 2026

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore

The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives


OneSource records Rs. 4,282 million revenue in Q4 FY26
News | May 15, 2026

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold


Senores Pharma doubles profit as sales surge 62%
News | May 15, 2026

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth


Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push
News | May 14, 2026

Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push

Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support